MEDICAL POLICY

Excellus
An independent licensee of the Blue Cross Blue Shield Association

MEDICAL POLICY DETAILS	
Medical Policy Title	**Ventricular Assist Devices (VADs)**
Policy Number	**7.01.07**
Category	**Technology Assessment**
Original Effective Date	**12/02/99**
Committee Approval Date	**10/18/01, 09/19/02, 09/16/04, 07/21/05, 07/20/06, 05/17/07, 05/14/08, 05/28/09, 05/27/10, 05/19/11, 05/24/12, 06/20/13, 05/22/14, 06/18/15, 06/16/16, 06/15/17, 06/21/18, 08/14/19, 08/15/19, 07/16/20, 07/15/21, 04/21/22, 03/23/23, 03/21/24**
Current Effective Date	**03/21/24**
Archived Date	**N/A**
Archive Review Date	**N/A**
Product Disclaimer	• *Services are contract dependent; if a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply.* • *If a commercial product (including an Essential Plan or Child Health Plus product), medical policy criteria apply to the benefit.* • *If a Medicaid product covers a specific service, and there are no New York State Medicaid guidelines (eMedNY) criteria, medical policy criteria apply to the benefit.* • *If a Medicare product (including Medicare HMO-Dual Special Needs Program(DSNP) product) covers a specific service, and there is no national or local Medicare coverage decision for the service, medical policy criteria apply to the benefit.* • *If a Medicare HMO-Dual Special Needs Program (DSNP) product DOES NOT cover a specific service, please refer to the Medicaid Product coverage line.*

POLICY STATEMENT

Based upon our criteria and assessment of the peer-reviewed literature, ventricular assist devices (VAD) approved for use by the U.S. Food and Drug Administration (FDA) have been medically proven to be effective and, therefore, are considered **medically appropriate** for **ANY** of the following indications:

I. **Bridge to transplantation** for patients who are diagnosed with severe ventricular heart failure and who meet **ALL** of the following criteria:
   A. are approved as a heart transplant candidate by an approved heart transplant center;
   B. have an imminent risk of dying before donor heart procurement;
   C. are on optimal inotropic (influencing the contractility of muscular tissue) support; **and**
   D. are on an intra-aortic balloon pump (IABP), unless contraindicated.

II. **Bridge to recovery** for post-cardiotomy patients who are unable to be weaned from cardiopulmonary bypass, or who have potentially reversible left ventricular dysfunction due to acute cardiogenic shock or acute myocarditis.

III. **Destination therapy** for adult patients who have end-stage heart failure, who meet **ALL** of the following criteria:
   A. Have been determined to be ineligible for heart transplantation (e.g., smoking);
   B. New York Heart Association (NYHA) Class III heart failure with dyspnea upon mild physical activity or NYHA Class IV;
   C. Left ventricular ejection fraction ≤ 25%; **and**
   D. Inotrope-dependent; OR cardiac index <2.2 liters/min/m^2, while not on inotropes and also meeting **one** of the following:
      1. On optimal medical management, based on current heart failure practice guidelines for at least 45 of the last 60 days and are failing to respond; **or**

2. Advanced heart failure for at least 14 days and dependent on intra-aortic balloon pump for at least 7 days.

E. have functional limitation, with a peak oxygen consumption of less than or equal to 14 ml/kg/min; **(**This criterion may be waived in persons who are balloon pump or intravenous inotrope dependent or are otherwise unable to perform exercise stress testing).
F. are of appropriate body size to support the Left (VAD) implantation.

IV. Percutaneous ventricular assist devices are considered **investigational** for all indications.

Refer to Corporate Medical Policy #7.01.65 Artificial Hearts

Refer to Corporate Medical Policy #11.01.03 Experimental or Investigational Services

POLICY GUIDELINES

I. The following guidelines may be used as hemodynamic selection criteria for bridge to transplant:
   A. The patient has either a left atrial pressure of 20m Hg or a cardiac index of less than 2.0 L/min/m2;
   B. The patient is generally being treated as an inpatient and has been categorized by the American Heart Association, or comparable, as Class IV CHF; and
   C. The patient is classified as Status I by the United Network for Organ Sharing (considered the highest priority for transplantation).

II. Contraindications for bridge to transplant:
   A. The patient has a condition that would generally exclude patients from heart transplant:
      1. Chronic irreversible hepatic, renal, or respiratory failure;
      2. Systemic infection; or
      3. Blood dyscrasia.
   B. The patient has an uncorrected heart valvular disease, due to the potential problems with adequate function of the VAD.

III. Individuals considered for VAD implantation as destination therapy should be evaluated for potential difficulties that would complicate and diminish the success of the implantation, including an assessment of patient compliance.

IV. The DeBakey VAD Child (HeartAssist 5 pediatric VAD) has Humanitarian Device Exemption (HDE) authorization from the FDA for use in providing temporary left side mechanical circulatory support as a bridge to cardiac transplantation for pediatric patients (ages five to 16 years, with BSA greater than or equal to 0.7 m^2 and less than 1.5 m^2) who are in NYHA Class IV end-stage heart failure, are refractory to medical therapy, and are (listed) candidates for cardiac transplantation. The Berlin Heart EXCOR VAD has also received FDA approval through the HDE process. It is indicated for children with severe, isolated left ventricular or biventricular dysfunction, who are candidates for cardiac transplant, and who require circulatory support.

V. In the MOMENTUM 3 trial, the centrifugal-flow Heart-Mate 3 left ventricular assist device was associated with a less frequent need for pump replacement than the axial-flow HeartMate II LVAD and was superior to the axial-flow pump with respect to survival free of disabling stroke or reoperation to replace or remove a malfunctioning device.

DESCRIPTION

Ventricular assist devices (VADs) fit into the general category of mechanical circulatory assist devices. VADs have been developed to provide mechanical support for patients with severe heart failure who are awaiting a heart transplant (bridge to transplant), for patients with post-cardiotomy or potentially reversible left ventricular dysfunction (bridge to recovery), and, in certain specific instances, for patients with end-stage heart failure who are not suitable transplant candidates (destination therapy).

Bridging to heart transplantation involves improving hemodynamics and restoring organ function such that a patient may have a better probability of surviving until a donor heart is available. Destination therapy is used for individuals with end-stage heart failure, who are not candidates for heart transplant and who are currently receiving optimal medical therapy with ACE inhibitors, beta-blockers, and inotropic drugs. Left ventricular assist devices (LVADs) are also used

temporarily for post-cardiotomy patients who cannot be weaned from cardiopulmonary bypass immediately following surgery. VADs have also been investigated as a bridge to recovery in patients with potentially reversible left ventricular dysfunction due to acute cardiogenic shock or acute myocarditis.

Percutaneous VADS are not implanted through an open-heart surgical procedure, the device is kept outside the body and is connected to the heart via a thin tube that is inserted percutaneously (through the skin) into an artery or vein. Percutaneous VADs can provide temporary heart support following heart surgery, heart attack, or other heart injury that impairs the ability of the ventricles to pump blood.

A variety of devices have received approval for marketing by the FDA, encompassing both biventricular and left ventricular devices. The type of device used is dependent upon specific FDA-labeled indications. These devices include, but are not limited to:

- HeartMate Sutures Not Applied Vented Electric Left Ventricular Assist System (SNAP VE LVAS) (Thoratec Corp.);
- HeartMate II LVAD (Thoratec Corp.);
- HeartMate 3 Left Ventricular Assist System (Thoratec Corp.);
- Impella 2.5/ Impella 5.0 (AbioMed Cardiovascular, Inc);
- Abiomed BVS 5000 Biventricular Support System (AbioMed Cardiovascular, Inc.).

RATIONALE

Bridge to transplantation by use of a VAD, allows patients to survive until a donor heart is available. Published studies report that use of a VAD does not compromise the success of subsequent heart transplantation and may actually improve post-transplant survival.

Bridge to recovery by a VAD is for patients with potentially reversible left ventricular dysfunction. Implantation of VADs provides circulatory support and allows myocardial recovery in post-cardiotomy cases where the patient cannot be weaned from cardiopulmonary bypass, and in patients with acute cardiogenic shock or acute myocarditis.

Destination therapy by a VAD is supported by the REMATCH study, a randomized controlled trial that compared LVAD device transplantation with optimal medical management in 129 patients with end-stage heart failure who were not candidates for cardiac transplantation. The trial showed that patients who received a VAD had a longer survival rate than those treated with optimal medical therapy. Median survival was increased by approximately 8.5 months. Although adverse events were more likely in the VAD group, these appeared to be outweighed by better outcomes on function; NYHA class was significantly improved, as was quality of life among those living to 12 months. Two years of additional observation on REMATCH patients (Park, 2005) substantiated the continuing survival benefit of LVAD support. LVAD treatment more than doubled the survival seen at two years over optimal medical management.

The HeartMate SNAP VE LVAS and the HeartMate XVE LVAS are two pulsatile devices that have received FDA approval for destination therapy. The Heartmate II LVAD, a continuous flow device, received FDA approval as destination therapy on January 20, 2010. The premarket approval included two-year data from a study cohort of 200 patients randomly assigned 2:1 to either a HeartMate XVE or a HeartMate II. Patients implanted with the HeartMate II device had statistically significant improved two-year survival versus those patients implanted with the HeartMate XVE, in addition to improved quality of life. 46% of the 134 patients implanted with the HeartMate II were still living after two years, with no disabling stroke or need for reoperation, device replacement or repair, compared with 11% in the 66-patient control group. Approval was contingent on a post-approval follow-up study involving 247 patients for either two years or until outcome by Thoratec.

HeartWare HVAD System (Medtronic, Inc.) was approved by the FDA in 20217 for the use in destination therapy in patients with advanced heart failure who are not candidates for heart transplant based on results from the ENDURANCE and ENDURANCE Supplemental trials. The HeartWare System is contraindicated in patients who cannot tolerate anticoagulation therapy. The HVAD pump implant kit was recalled on April 11, 2022.

The HeartMate II (Thoratec) was the first continuous flow device to receive FDA approval as a bridge to transplant for treatment of advanced-stage heart failure. The approval was based on one-year follow-up data from the first 194 HeartMate II bridge-to-transplant patients enrolled in the trial. Results included in the final PMA submission were:

- The median duration of support was 132 days, and the cumulative patient support in the trial was 109 years.
- Survival to cardiac transplantation, recovery or ongoing on HeartMate II support, was 80% at six months and 77% at one year.
- 84% of the patients survived to hospital discharge or transplantation.
- Significant improvements were observed across all measures of functional status and quality of life, as compared to baseline status.
- The incidence of major adverse events with comparable definitions, including infections, strokes, and bleeding requiring surgery, was significantly lower than what was clinically observed in the previous bridge-to-transplant study of the HeartMate.

The HeartMate 3 Left Ventricular Assist System (Thoratec) was approved by the FDA on August 23, 2017. Per the manufacturer's website, the HeartMate 3 system can pump up to 10 liters of blood per minute and is the only commercially-approved continuous flow implantable left ventricular assist system to utilize Full MagLev (fully magnetically-levitated) flow technology, which allows the device's rotor to be "suspended" by magnetic forces—rather than bearings—with the goal of being able to more gently pass the blood cells through the pump. The magnets keep the rotor in place by calibrating tens of thousands of times per second, to ensure that it stays suspended and centered within the pump, no matter the speed settings used by a physician. This ensures that the pump is performing effectively while continuing to deliver the best patient therapy possible. The HeartMate 3 system also uses the industry's widest pump pathway, designed so the blood cells are not damaged when passing through. The system also relies on a built-in "pulse" programmed to help ensure the blood continues to move through without becoming static, thereby reducing the risk of blood clot formation. The HeartMate 3 blood pump should not be used in patients who cannot tolerate, or who are allergic to, anticoagulation therapy (blood thinners), because these medicines are required to prevent blood clots from forming in the pump.

The MOMENTUM 3 trial compared HeartMate 3 centrifugal continuous-flow device with the HeartMate II axial continuous-flow device in patients indicated for circulatory support as a bridge to transplant or destination therapy; inclusion criteria included:

- NYHA Class III heart failure with dyspnea upon mild physical activity or NYHA Class IV;
- Left ventricular ejection fraction ≤ 25%;
- Inotrope-dependent OR cardiac index <2.2 liters/min/m^2 while not on inotropes and subjects must also meet the following: On optimal medical management for at least 45 of the last 60 days and failing to respond or with advanced heart failure for at least 14 days and dependent on intra-aortic balloon pump for ≥7 days.

HeartMate 3 received PMA approval as a bridge to transplant therapy in August 2017 and as destination therapy in October 2018. The destination therapy indication was based on two-year results from MOMENTUM 3, which showed superiority of the HeartMate 3 device compared to HeartMate II on the composite primary outcome, survival at two years free of disabling stroke or reoperation to replace a malfunctioning device (RR, 0.84; 95% CI, 0.78 to 0.91, p<.001)(Mehra et al., 2019). Prevalence of stroke at two years was lower in the HeartMate 3 than the HeartMate 2 group (10.1% vs 19.2%; p=.02) (Columbo et al.,2019). Measures of functional capacity and Health-Related quality of life did not differ between the two devices at 6 months (Cowger et al., 2018).

MicroMed HeartAssist 5 (formally the DeBakey VAD Child). It is a ventricular assist device for home and hospital use, for children ages five to 16 years who are awaiting a heart transplant. It was approved data showed that the device had a reasonable probability of being safe and effective in children. Publications have reported positive outcomes for children using VADs as a bridge to transplantation. Davies, et al. (2008) reported on the use of VADs in pediatric patients undergoing heart transplantation. Their analysis concluded that pediatric patients requiring a pre-transplantation VAD have similar long-term survival to those not receiving mechanical circulatory support**.**

The Berlin Heart EXCOR Pediatric VAD has become the first pediatric-specific VAD that has gained widespread acceptance in North America. The Berlin Heart investigational device exemption (IDE) trial was successfully completed. It is the only Pediatric VAD that can be used for newborns, infants and small children ≤ 25 kg.

AbioMed, Inc announced the FDA Section 510(k) clearance for its Impella 2.5 cardiac assist device on June 2, 2008. The Impella 2.5 is inserted percutaneously via the femoral artery into the left ventricle, to provide partial circulatory support for periods up to six hours. Up to 2.4 liters of blood per minute are delivered by the pump from the left ventricle into the ascending aorta, providing the heart with active support in critical situations. The PROTECT I trial (Dixon, et al. 2009) evaluated the effectiveness of the Impella 2.5 (n = 20) in patients undergoing high-risk percutaneous coronary intervention (PCI) at seven centers. Eligible patients had a left ventricular ejection fraction (LVEF) of less than 35%. The Impella 2.5 device was implanted successfully in all patients. The mean duration of circulatory support was 1.7 ± 0.6 h (range: 0.4 to 2.5 h). Mean pump flow during PCI was 2.2 ± 0.3 l/min. At 30 days, the incidence of major adverse cardiac events was 20% (two patients had a periprocedural myocardial infarction; two patients died at days 12 and 14). There was no evidence of aortic valve injury, cardiac perforation, or limb ischemia. Two patients (10%) developed mild, transient hemolysis without clinical sequelae. None of the patients developed hemodynamic compromise during PCI. Other studies investigating the Impella device, although limited by small sample populations, have demonstrated its efficacy in providing circulatory support during high-risk percutaneous revascularization procedures and in post-cardiotomy patients.

The PROTECT II trial was a prospective, randomized clinical trial that identified and characterized a population of high-risk patients undergoing nonemergent PCI. In these patients, PCI resulted in a marked reduction of symptoms and increased left ventricular function. Hemodynamic support with Impella 2.5 did not result in a superior outcome of the primary end point at 30 days but showed a strong trend to superior outcome at 90 days in the total cohort and a significant improvement in the prespecified per protocol analysis at 90 days. Important adverse events continued to occur after 30-day follow-up, suggesting that intense medical observation is required for at least 90 days in these patients. The trial was terminated prematurely because of the data safety monitoring board's determination of futility. (O'Neill et al., 2012).

Abiomed's Impella expandable percutaneous heart pump (ECP) was granted breakthrough device designation in 2021. The designation means the FDA will prioritize Impella ECP's regulatory review processes including design iterations, clinical study protocols and pre-market approval (PMA) application. Impella ECP is the smallest heart pump in the world and the first to be compatible with small bore access and closure techniques. It measures 9 French (3 millimeters) in diameter upon insertion and removal from the body. While in the heart, it expands to support the heart's pumping function, providing flow greater than 3.5 L/min. This device is considered only for investigational use.

The American Association for thoracic Surgery (AATS) and International Society for Heart and Lung Transplantation (ISHLT) guidelines (Atluri et al, 2020) discusses selected topics pertaining to mechanical circulatory support. The recommendations include preoperative evaluation and optimization and the use of PVADs in cardiogenic shock:

Techniques in cardiogenic shock (including, but limited to):

- Percutaneous right ventricular assist device support should be considered for cardiogenic shock from primary right ventricular failure (Class of recommendations (COR) IIa, Level of evidence (LOE) B).
- Percutaneous LV to aorta pumps of appropriate size should be considered for cardiogenic shock from primary LV failure (Class of recommendations (COR) IIa, Level of evidence (LOE) B).
- IABP support is recommended for cardiogenic shock complicating acute myocardial infarction, but additional mechanical support may be needed if prompt hemodynamic improvement is not forthcoming (COR IIa, LOE A).

CODES

- *Eligibility for reimbursement is based upon the benefits set forth in the member's subscriber contract.*
- *CODES MAY NOT BE COVERED UNDER ALL CIRCUMSTANCES. PLEASE READ THE POLICY AND GUIDELINES STATEMENTS CAREFULLY.*
- *Codes may not be all inclusive as the AMA and CMS code updates may occur more frequently than policy updates.*
- *Code Key: Experimental/Investigational = (E/I), Not medically necessary/ appropriate = (NMN).*

CPT Codes

Code	Description
33975	Insertion of ventricular assist device; extracorporeal, single ventricle
33976	Insertion of ventricular assist device; extracorporeal, biventricular

Code	Description
33977	Removal of ventricular assist device; extracorporeal, single ventricle
33978	Removal of ventricular assist device; extracorporeal, biventricular
33979	Insertion of ventricular assist device, implantable intracorporeal, single ventricle
33980	Removal of ventricular assist device, implantable intracorporeal, single ventricle
33981	Replacement of extracorporeal ventricular assist device, single or biventricular, pump(s), single or each pump
33982	Replacement of ventricular assist device pump(s); implantable intracorporeal, single ventricle, without cardiopulmonary bypass
33983	Replacement of ventricular assist device pump(s); implantable intracorporeal, single ventricle, with cardiopulmonary bypass
33990 (**E/I**)	Insertion of ventricular assist device, percutaneous including radiological supervision and interpretation; left heart, arterial access only
33991 (**E/I**)	Insertion of ventricular assist device, percutaneous including radiological supervision and interpretation; left heart, both arterial and venous access, with transseptal puncture
33992 (**E/I**)	Removal of percutaneous ventricular assist device, atrial or atrial venous cannula(s), at separate and distinct session from insertion
33995 **(E/I)**	Insertion of ventricular assist device, percutaneous, including radiological supervision and interpretation; right heart, venous access only
33997 (**E/I**)	Removal of percutaneous right heart ventricular assist device, venous cannula, at separate and distinct session from insertion
93750	Interrogation of ventricular assist device (VAD), in person, with physician or other qualified health care professional analysis of device parameters (eg, drivelines, alarms, power surges), review of device function (eg, flow and volume status, septum status, recovery), with programming, if performed, and report

HCPCS Codes

Code	Description
Q0477	Power module patient cable for use with electric or electric/pneumatic ventricular assist device, replacement only
Q0480-Q0509	VAD components (code range)

ICD10 Codes

Code	Description
A18.84	Tuberculosis of heart
I09.81	Rheumatic heart failure
I11.0	Hypertensive heart disease with heart failure
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease
I21.01-I22.9	ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction (code range)
I40.0-I41	Acute myocarditis and myocarditis in diseases classified elsewhere (code range)
I50.1-I50.9	Heart failure (code range)
R57.0	Cardiogenic shock

REFERENCES

Abdullah KQA, et al. Impella use in real-world cardiogenic shock patients: Sobering outcomes. PLoS One 2021 Feb 26;16(2):e0247667.

Ahmed H, et al. U.S Trends in pediatric VAD utilization – where are we now? Journal Heart and Lung Transplantation 2020 Apr:39(4s):529.

Ardito V, et al. Impella Versus VA-ECMO for Patients with Cardiogenic Shock: Comprehensive Systematic Literature Review and Meta-Analyses. J Cardiovasc Dev Dis 2023 Apr 5;10(4):158.

*Blume ED, et al. Outcomes of children bridged to heart transplantation with ventricular assist devices: a multi-institutional study. Circ 2006 May 16;113(19):2313-9.

Bochaton T, et al. Mechanical circulatory support with the Impella LP5.0 pump and an intra-aortic balloon pump for cardiogenic shock in acute myocardial infarction: The IMPELLA-STIC randomized study. Arch Cardiovasc Dis 2020;113(4):237-243.

*Brancaccio G, et al. Ventricular assist devices as a bridge to heart transplantation or as destination therapy in pediatric patients. Transplant Proc 2012 Sep;44(7):2007-12.

Burzotta F, et al. Long-term outcomes of extent of revascularization in complex high risk and indicated patients undergoing impella-protected Percutaneous Coronary Intervention: Report from the Roma-Verona Registry. J Interv Cardiol 2019 Apr 9;2019:5243913.

Chandrasekar B. Mechanical circulatory support with Impella in percutaneous coronary intervention: current status. American Heart Journal Plus: Cardiology Research and Practice 2021 Jan;1:100002

*Clegg AJ, et al. Clinical and cost-effectiveness of left ventricular assist devices as destination therapy for people with end-stage heart failure: a systematic review and economic evaluation. Int J Technol Assess Health Care 2007 Spring;23(2):261-8.

*Colombo PC, et al. Comprehensive Analysis of Stroke in the Long-Term Cohort of the MOMENTUM 3 Study. Circulation 2019 Jan 8;139(2):155-168.

*Cook JL, American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Radiology and Intervention; and Council on Cardiovascular Surgery and Anesthesia. Recommendations for the Use of Mechanical Circulatory Support: Ambulatory and Community Patient Care: A Scientific Statement from the American Heart Association. Circulation 2017 Jun 20;135(25):e1145-e1158.

*Cowger JA, et al. Quality of life and functional capacity outcomes in the MOMENTUM 3 trial at 6 months: A call for new metrics for left ventricular assist device patients. J Heart Lung Transplant 2018 Jan;37(1):15-24

*Davies RR, et al. The use of mechanical circulatory support as a bridge to transplantation in pediatric patients: an analysis of the United Network for Organ Sharing database. J Thorac Cardiovasc Surg 2008 Feb; 135(2): 421-7, 427.e1.

*De By TM, et al. The European Registry for Patients with Mechanical Circulatory Support (EUROMACS): first annual report. Eur J Cardiothorac Surg 2014 May;47(5):770-7.

*Dixon SR, Henriques JP, Mauri L, et al. A prospective feasibility trial investigating the use of the Impella 2.5 system in patients undergoing high-risk percutaneous coronary intervention (ThePROTECT I Trial): Initial U.S. experience. JACC Cardiovasc Interv 2009;2(2):91-96.

*Donneyong M, et al. The association of pre-transplant HeartMate II left ventricular assist device implantation. Circulation 2014 Mar 11;129(10):1161-6.

*Dunlay SM, et al. Frailty and outcomes after implantation of left ventricular assist device as destination therapy. J Heart Lung Transplant 2014 Apr;33(4):359-65.

Frain K, Rees P. Intra-aortic balloon pump versus percutaneous Impella in emergency revascularisation for myocardial infarction and cardiogenic shock: systematic review. Perfusion 2024 Jan;39(1):45-59.

*Fraser CD, et al. Prospective trial of a pediatric ventricular assist device. N Engl J Med 2012 Aug 9;367(6):532-41.

Gandhi KD, et al. Left ventricular unloading with Impella versus IABP in patients with va-ecmo: a systematic review and meta-analysis. Am J Cardiol 2023 Dec 1;208:53-59.

*Gronda E, et al. Heart rhythm considerations in heart transplant candidates and considerations for ventricular assist devices: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates-2006. J Heart Lung Transplant 2006 Sep;25(9):1043-56.

*Hetzer R, et al. Role of paediatric assist device in bridge to transplant. Ann cardiothroac Surg 2018;7(1):82-98.

*Hetzer R, et al. Single-center experience with treatment of cardiogenic shock in children by pediatric ventricular assist devices. J Thorac Cardiovasc Surg 2011 Mar;141(3):616-623. e1.

Hetzer R, et al. Pediatric ventricular assist devices: what are the key considerations and requirements? Expert Review of Medical Devices, 2020 17:1, 57-74.

Iannaccone M, et al. Short term outcomes of Impella in cardiogenic shock: A review and meta-analysis of observational studies. Int J Cardiol 2021 Feb 1;324:44-51.

Jani M, et al. Decreased frequency of transplantation and lower post-transplant survival free of re-transplantation in LVAD patients with the new heart transplant allocation system. Clin Transplant 2022 Jan;36(1):e14493.

*Jorde UP, et al. Results of the destination therapy post-FDA-approval study with a continuous flow left ventricular assist device: a prospective study using the INTERMACS Registry. J Am Coll Cardio 2014 May 6;63(17):1751-7.

*Kirklin JK, et al. American Association for Thoracic Surgery/International Society for Heart and Lung Transplantation guidelines on selected topics in mechanical circulatory support. J Heart Lung Transplant 2020 Mar;39(3):187-219.

*Lietz K, et al. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection. Circulation 2007 Jul 31;116(5):497-505.

Loehn T, et al. Long term survival after early unloading with Impella CP in acute myocardial infarction complicated by cardiogenic shock. Eur Heart J Acute Cardiovasc Care 2020 Mar;9(2):149-157.

Luni FK, et al. Percutaneous left ventricular assist device support during ablation of ventricular tachycardia: a meta-analysis of current evidence. J Cardiovasc Electrophysiol 2019 Jun;30(6):886-895.

*Mehra MR, et al. A Fully Magnetically Levitated Left Ventricular Assist Device - Final Report. N Engl J Med 2019 Apr 25;380(17):1618-1627.

*Mehra MR, et al. Primary results of long-term outcomes in the MOMENTUM 3 pivotal trial and continued access protocol study phase: a study of 2200 HeartMate 3 left ventricular assist device implants. Eur J Heart Fail 2021 Aug;23(8):1392-1400.

*Morales DL, et al. Bridging children of all sizes to cardiac transplantation: the initial multicenter North American experience with the Berlin Heart EXCOR ventricular assist device. J Heart Lung Transplant 2011 Jan;30(1):1-8.

*Moreno SG, et al. Cost-effectiveness of the implantable HeartMate II left ventricular assist device for patients awaiting heart transplantation. J Heart Lung Transplant 2012 May;31(5):450-8.

*Morgan JA, et al. Stroke while on long-term left ventricular assist device support: incidence, outcome, and predictors. ASAIO J 2014 May-Jun;60(3):284-9.

Mullan CW, et al. Changes in use of left ventricular assist devices as bridge to transplantation with new heart allocation policy. JACC Heart Fail 2021 Jun;9(6):420-429.

*O'Neill WW, et al. A prospective, randomized clinical trial of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention: the PROTECT II study. Circulation 2012 Oct 2;126(14):1717-27.

Nayak A, et al. Predictors of 5-year mortality in patients managed with a magnetically levitated left ventricular assist device. J Am Coll Cardiol 2023 Aug 29;82(9):771-781.

Ouweneel DM, et al. Real-life use of left ventricular circulatory support with Impella in cardiogenic shock after acute myocardial infarction: 12 years AMC experience. Eur Heart J Acute Cardiovasc Care 2019 Jun;8(4):338-349.

*Park SJ, et al. Left ventricular assist devices as destination therapy: a new look at survival. J Thorac Cardiovasc Surg 2005 Jan; 129(1): 9-17.

*Patel CB, et al. A contemporary review of mechanical circulatory support. J Heart Lung Transplant 2014 Jul;33(7):667-74.

*Rogers JG, et al. Chronic mechanical circulatory support for inotrope-dependent heart failure patients who are not transplant candidates: results of the INTrEPID Trial. J Am Coll Cardiol 2007 Aug 21;50(8):741-7.

Schrage and Westermann. Mechanical circulatory support devices in cardiogenic shock and acute heart failure: current evidence. Curr Opin Crit Care 2019;25:391-396.

*Sharma MS, et al. Ventricular assist device support in children and adolescents as a bridge to heart transplantation. Ann Thorac Surg 2006 Sep;82(3):926-32.

Shi W, et al. Percutaneous mechanical circulatory support devices in high-risk patients undergoing percutaneous coronary intervention: A meta-analysis of randomized trials. Medicine 2019;98:37.

*Shuhaiber JH, et al. The influence of preoperative use of ventricular assist devices on survival after heart transplantation: propensity score matched analysis. BMJ 2010 Feb10;340:c392.

*Starling RC, et al. results of the post-U.S. Food and Drug Administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: a prospective study using the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Col Cardiol 2011 May 10;57(19):1890-8.

Tatum RT, et al. Impact of mechanical circulatory support on donor heart allocation: past, present, and future. Rev Cardiovasc Med 2021 Mar 30;22(1):25-32.

von Mackensen JKR, et al. Mechanical circulatory support strategies in takotsubo syndrome with cardiogenic shock: a systematic review. J Clin Med 2024 Jan 15;13(2):473.

Wendling, P. Medtronic yanks Heartware VAD, calls for halt to new implants. Medscape 2021, June 3.

Yin MY, et al. Post-transplant outcome in patients bridged to transplant with temporary mechanical circulatory support devices. J Heart Lung Transplant 2019 Aug;38(8):858-869.

*Key Article

KEY WORDS

Bridge to heart transplant, Assist Devices, ventricular, LVAD, VAD, Destination Therapy

CMS COVERAGE FOR MEDICARE PRODUCT MEMBERS

There is currently a National Coverage Determination (NCD) for Ventricular Assist Devices (20.9.1). Please refer to the following NCD website for Medicare members:

https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?ncdid=360&ncdver=2&keyword=ventricular%20assist&keywordType=starts&areaId=all&docType=NCD&contractOption=all&sortBy=relevance&bc=AAAAAAQAAAAA& accessed 01/19/24.